The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...

The 35-year-old software developer, based in China's western metropolis of Chengdu, is about to start his third month on Ozempic, the brand name that pharmaceutical giant Novo Nordisk gives to ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.

US FDA declares Wegovy & Ozempic shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses: Plainsboro, New Jersey Monday, February 24, ...

Him & Hers (HIMS) lost its jaw-dropping momentum last week. After peaking at nearly $73, shares closed at $49.28, down by ...

The blistering rally in Hims & Hers Health Inc. that’s captivated meme-stock traders has ground to a halt, setting up a ...